Title

Type I interferon responses contribute to immune protection against mycobacterial infection

Authors

Andrea Szydlo-Shein[1], Blanca Sanz-Magallón Duque de Estrada[1], Joshua Rosenheim[1], Carolin T.
Turner[1], Evdokia Tsaliki[1], Marc C. I. Lipman[2,3], Heinke Kunst[4,5], Gabriele Pollara[1], Philip M. Elks[6],
Jean-Pierre Levraud[7], Elspeth M. Payne[8], Mahdad Noursadeghi[1], Gillian S. Tomlinson[1]*

Affiliations

[1]Division of Infection and Immunity, University College London, London, UK

[2]Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK

[3]UCL Respiratory, University College London, London, UK

[4]Barts Health NHS Trust, London, UK

[5]Blizard Institute, Queen Mary University of London, London, UK

[6]The Bateson Centre, School of Medicine and Population Health, The University of Sheffield,
Sheffield, UK

[7]Université Paris-Saclay, CNRS UMR9197, Institut Pasteur, Université Paris-Cité, Institut des
Neurosciences Paris-Saclay, 91400 Saclay, France

[8]Research Department of Haematology, Cancer Institute, University College London, London, UK

*Corresponding author

Corresponding author

Gillian S. Tomlinson, Email: g.tomlinson@ucl.ac.uk

ABSTRACT

Reasons for the spectrum of severity of active tuberculosis (TB) disease are incompletely understood. We sought to identify master regulators of host immune responses that determine disease severity in pulmonary TB. We performed molecular profiling of human in vivo immune responses to discover associations with the extent of radiographic TB disease in a patient cohort. We then undertook mechanistic studies to test causality for the observed associations using the zebrafish larval *Mycobacterium marinum* infection model. Transcriptional profiling of human immune recall responses to tuberculin skin test (TST) challenge, a surrogate for immune responses to TB in the lung, revealed that type I interferon activity in the TST transcriptome was inversely associated with radiological disease severity. Abrogation of type I interferon signalling, achieved by CRISPR-mediated mutagenesis of *stat2*, led to increased susceptibility of zebrafish larvae to *M. marinum* infection, as a result of reduced recruitment of myeloid cells required to restrict mycobacterial growth, to the site of disease. Our data support a host protective role for type I interferon responses in mycobacterial infection, with potential applications for risk-stratification of adverse outcomes and development of a host-directed therapy to mitigate against severe disease.

ONE SENTENCE SUMMARY

Type I interferon responses contribute to host immune protection in mycobacterial infection by recruitment of myeloid cells to the site of disease.

INTRODUCTION

Mycobacterium tuberculosis (Mtb) infection results in diverse clinical manifestations, ranging from
asymptomatic infection to active tuberculosis (TB), which comprises an enormous spectrum of
disease severity *(1, 2)*. Although we know that immune responses contribute to the risk of disease,
current understanding of the role of immune response variation in disease severity is limited.
Identification of immune correlates of disease severity may offer new insights into the immune
pathways that contribute to protection and pathogenesis. This is necessary to enable novel vaccine
design and evaluation, stratify disease risk in people who become infected and inform development
of novel host-directed therapies to shorten treatment regimens, mitigate against antimicrobial
resistance, and against the chronic sequelae of tissue injury in TB *(3)*.

Variation in tissue immunology of human TB at the site of established disease is likely confounded
by differences in the chronicity of the disease process. To overcome this limitation, we evaluated in
vivo immune responses at the site of a standardised antigenic challenge using the tuberculin skin
test (TST). We have previously shown that transcriptional profiling of skin biopsies from the site of
the TST provides comprehensive molecular and systems level evaluation of human in vivo immune
responses to Mtb with significantly greater sensitivity than conventional clinical and histological
assessments *(4, 5)*. The TST gene signature is enriched within pulmonary TB granulomas and
accounts for genome-wide differences in the transcriptomes of TB infected lung compared to healthy
lung tissue *(5, 6)*. Therefore, the TST provides a faithful and readily accessible surrogate to study
immune responses at the site of TB disease.

In the present study, we identified quantitative variation in immune pathways in the TST response
correlated with the severity of human TB disease, and then tested the hypothesis that these
pathways were causally related to outcomes of *Mycobacterium marinum* infection in zebrafish larvae.
This natural host-pathogen interaction generates granulomatous inflammation that recapitulates key
aspects of human TB pathology and in particular, provides unparalleled opportunities to study innate
immune responses in isolation, given the absence of functional adaptive immunity until 3-4 weeks
(7). Our innovative strategy revealed an inverse relationship between type I interferon activity and
radiographic severity of human TB, suggesting a host-protective role for type I interferons, that we
confirmed in zebrafish larvae by showing that mutagenesis of *stat2* to model abrogation of
downstream type I interferon signalling led to increased severity of *M. marinum* infection.

RESULTS

Outlier analysis of the TST transcriptome defines human in vivo immune responses to
active tuberculosis

We supplemented data from our previously reported TST transcriptional responses *(8)* to provide a
total sample size of 51 people with microbiologically confirmed pulmonary TB who were within one
month of commencing anti-tuberculous chemotherapy (Table 1, Fig. S1A, B). We evaluated disease
severity using a published radiographic scoring system which incorporates extent of disease and the
presence of cavitation on chest x-ray *(9)*. In order to capture the inter-individual variation in immune
response to the mycobacterial challenge, outlier profile analysis *(10)* was used to identify transcripts
in the TST of each individual that were significantly enriched compared to gene expression in control
data from skin biopsies at the site of saline injections. The integrated list of outlier genes statistically
enriched in TST samples compared to control saline samples from all 51 individuals defined an active
TB TST transcriptome comprised of 3222 transcripts. This analysis revealed that although some
aspects of the TST response are consistent in all people, there is also considerable variability
between individuals (Fig. S1C). The 3222 transcripts identified by this approach, were enriched for
canonical pathways involved in cell mediated responses, consistent with our previous description of
the TST gene signature identified by conventional differential gene expression analysis *(5, 8)* (Fig.
S1D).

Reduced type I interferon activity in the TST transcriptome is associated with increased
severity of human TB disease

Next, we sought to identify immunological pathways correlated with disease severity. We identified
individual genes in the TST transcriptome that showed statistically significant correlations with the

radiographic severity score. We subjected these genes to Ingenuity Pathway Analysis upstream
regulator analysis to collate groups of co-regulated genes (Fig. 1A and Fig. S2A). These were
annotated by their upstream regulators at the level of cytokines, transmembrane receptors, kinases
and transcriptional regulators, representing the key components of signalling pathways which
mediate immune responses. To provide increased confidence that these modules represented co-
regulated genes in each molecular pathway, we retained only those that had significantly greater co-
correlated expression than modules of genes randomly selected from our TST transcriptomes *(11)*.
111 modules were identified among genes inversely correlated with radiographic TB severity,
suggesting they may contribute to host protection against severe disease (Fig. 1A-C and Fig. S2B).
These included transcriptional modules representing pro-inflammatory cytokine activity (tumour
necrosis factor alpha and interleukin (IL)1 beta), interferon gamma and T cell activity, consistent with
existing evidence predominantly supporting their protective roles in TB *(12)* (Fig. 1B). In addition, we
found enrichment of multiple co-regulated gene networks attributed to type I interferon signalling,
suggesting that type I interferon responses may also contribute to host protection in mycobacterial
infection (Fig. 1B, C). Interferon gamma was also predicted to regulate one of only two small putative
networks within genes positively correlated with disease severity; the other driven by TCL1A, an AKT
kinase activator that promotes cellular survival *(13)* (Fig. S2C).

To validate the immunological responses predicted to be associated with disease severity by
upstream regulator analysis, we quantified the expression of two independently derived and largely
non-overlapping type I interferon inducible gene modules reflecting the biological activity of type I
interferons (Table S1) *(5, 8)*, within the TB TST transcriptome (Fig. 1D). This provided independent
validation of the inverse relationship between type I interferon responses and radiographic severity
of TB (Fig. 1E), suggestive of a host-protective role. By contrast, the expression of the entire TST
transcriptome and that of three distinct independently derived interferon gamma inducible gene
modules *(5)* (Table S1) did not correlate with disease severity (Fig. S3).

stat2 CRISPant zebrafish larvae exhibit increased susceptibility to *M. marinum* infection

The TST transcriptome does not solely reflect anti-mycobacterial T cell memory *(4)* and type I
interferons are primarily induced following activation of innate immune recognition pathways *(14)*.
Therefore, to evaluate whether impaired type I interferon responses cause more severe
mycobacterial disease, we exploited the zebrafish larval *M. marinum* infection model, which allows
exclusive assessment of innate immunity *(7)*. The mammalian canonical type I interferon signalling
pathway is highly conserved in zebrafish *(15, 16)* (Fig. 2A). First, we confirmed that intravenous
M. marinum infection of wild type zebrafish larvae induces a type I interferon response, as evidenced
by enrichment for two distinct independently derived transcriptional modules reflecting type I
interferon activity *(11, 16)* (Table S1) within genome-wide transcriptomic data obtained after four
days of mycobacterial growth (Fig. 2B, C). To block downstream type I interferon signalling we used
CRISPR-mediated mutagenesis of *stat2*, a subunit of the interferon stimulated gene factor (ISGF)3,
the principal transcription factor complex which induces expression of type I interferon stimulated
genes (ISG) *(17–19)*, for which there is a single zebrafish orthologue *(15)* (Fig. 2A). Injection of three
guide RNA/Cas9 ribonucleoprotein (RNP) complexes each targeting a distinct *stat2* exon, into one
cell stage wild type zebrafish embryos led to >90% efficient mutagenesis, confirmed by next-
generation sequencing (Fig. S4A and Fig. S5A). We verified loss of functional downstream type I
interferon signalling by showing that induction of the classical ISG Mxa *(16, 19)* by recombinant
interferon phi 1, measured by expression of a reporter *mxa:mCherry* transgene, was significantly
attenuated in *stat2* CRISPants compared to siblings injected with "scrambled" (negative control)
RNPs designed to lack genomic targets (Fig. S4B and Fig. S5B-C). *stat2* CRISPants developed
normally up to five days post-fertilisation (Fig. S5B).

There was no difference in survival of *M. marinum* infected *stat2* CRISPants and scrambled RNP
injected siblings (Fig. 3A, B) within the timeframe of our experiments. However, mycobacterial
burden, the number of bacterial foci and the spatial dissemination of bacteria, determined by
quantitation of fluorescent foci of *M. marinum*, were all significantly higher in intravenously infected
stat2 CRISPants compared to control RNP injected siblings, indicative of more severe disease (Fig.
3A, C-E). These findings are consistent with a host protective role for type I interferons in
mycobacterial infection, as suggested by our observation of an association between reduced type I
interferon activity and increased disease severity in human TB (Fig. 1).

Steady state neutrophil numbers are reduced in *stat2* CRISPant zebrafish larvae

Macrophages are critically important for control of *M. marinum* infection in zebrafish larvae *(20–22)*
and neutrophils may also contribute to mycobacterial killing *(23, 24)*. Therefore, to investigate the
mechanisms by which *stat2* deficiency leads to worse mycobacterial infection we used transgenic
zebrafish lines with fluorescent immune cell lineages to generate *stat2* CRISPants that have
fluorescent macrophages or neutrophils. First, we asked whether *stat2* disruption impacted steady
state macrophage or neutrophil numbers. We demonstrated by quantitative fluorescence
microscopy, using integrated fluorescence as a surrogate for cell number, that *stat2* deficiency did
not affect baseline macrophage numbers (Fig. 4A, B). However, it was associated with reduced
neutrophil numbers (Fig. 4C, D).

Recruitment of macrophages but not neutrophils to the site of sterile injury is *stat2*
dependent

Type I interferons have previously been shown to influence cellular migration *(14, 25)*. Therefore,
we tested macrophage and neutrophil recruitment in *stat2* CRISPants using a tailfin transection
model of sterile injury, most commonly used to evaluate neutrophil recruitment *(26)* (Fig. S4C). The
timing of neutrophil homing to the site of sterile tail fin transection was normal in *stat2* CRISPants,
with maximal accumulation at six hours and dissipation of recruited cells becoming evident by 24
hours, similar to that of control RNP injected embryos (Fig. 5A, B) and in keeping with previous
studies *(26, 27)*. Despite baseline neutropenia, the number of neutrophils at the wound site at the
point of maximal recruitment in *stat2* CRISPants exceeded that of control RNP injected embryos.
But by 24 hours the number of neutrophils at the injury site was significantly reduced in *stat2*
CRISPants, likely reflecting the attenuated increase in total neutrophil numbers in response to the
acute inflammatory challenge (Fig. 5C, D).

As previously reported, macrophage recruitment to the tail wound site was slower than that of
neutrophils *(27, 28)*. Very few macrophages were present at the tailfin transection site by one hour
in either *stat2* disrupted or control transgenic larvae, but recruitment progressively increased until 24
hours in both groups (Fig. 6). Fewer macrophages were found in the vicinity of the wound site at all
time points post-injury in *stat2* CRISPant transgenic embryos compared to control RNP injected
siblings, the majority being located outwith the tailfin (Fig. 6). Taken together these data suggest that
stat2 is necessary for macrophage recruitment but non-essential for neutrophil recruitment to a
sterile injury site. In addition, baseline neutropenia did not impact the number of cells localised to the
wound at peak neutrophil recruitment.

Recruitment of myeloid cells to the site of *M. marinum* infection is *stat2* dependent

Next we focused on macrophage recruitment to the site of mycobacterial infection because this has
been reported to be crucial for control of *M. marinum* growth in zebrafish larvae *(21)*. We found a
significant reduction in the number of macrophages recruited to the site of localised hindbrain
M. marinum infection in *stat2* deficient transgenic zebrafish larvae compared to their counterparts
injected with scrambled RNPs (Fig. S4D and Fig. 7A, B). We then evaluated whether *stat2* disruption
affected recruitment of neutrophils to the site of mycobacterial infection. We found that in contrast to
their normal peak recruitment to a sterile wound, the number of neutrophils attracted to the site of
mycobacterial disease was also significantly diminished in *stat2* CRISPants (Fig 7C, D). Collectively,
these results demonstrate that myeloid cell recruitment to the site of *M. marinum* infection is *stat2*
dependent.

In total, the recruitment studies suggest that *stat2* disruption leads to a broad defect in macrophage
recruitment to both infectious and non-infectious inflammatory foci. By contrast, *stat2* is non-essential
for neutrophil migration to sterile injury. The latter finding is consistent with defective migration, rather
than neutropenia, being the principal mechanism for reduced neutrophil numbers at the site of
M. marinum infection.

DISCUSSION

We have taken an innovative approach, combining molecular and systems level evaluation of human
immune responses to a standardised experimental challenge, to identify master regulators of

biological pathways associated with TB disease severity. We experimentally validated host factors
responsible for differences in phenotype using a relevant, tractable animal model which represents
a natural host-pathogen pairing *(7)*. Molecular interrogation of human in vivo responses to Mtb
revealed that reduced type I interferon activity within the TST transcriptome was associated with
worse pulmonary disease. Deficient type I interferon signalling, achieved by genetic disruption of
stat2, led to more severe mycobacterial infection in zebrafish larvae, via a mechanism involving
impaired recruitment of macrophages and neutrophils to the site of disease and reduced neutrophil
numbers at baseline. Taken together our results demonstrate an important role for type I interferon
responses in contributing to innate immune protection against mycobacterial disease.

Peripheral blood interferon-inducible gene expression that diminishes with successful treatment is
detectable in human active TB *(29–31)*. These transcriptional signatures comprise both type I and
type II interferon inducible genes but have mainly been interpreted as type I interferon responses,
fostering the view that type I interferons are detrimental to the host in human TB. Mouse data
predominantly suggest that type I interferon responses contribute to increased susceptibility to
mycobacterial infection by mechanisms including antagonism of IL1 mediated protection *(32–34)*
and reduced responsiveness of macrophages to interferon gamma *(35)*. However, this phenotype
has not been universally observed, likely due to differences in host and pathogen genetics *(36)*.
Moreover, impaired type I interferon responses are generally associated with relatively minor
differences in bacterial burden or survival *(36)*. Of note, Mtb is not a natural mouse pathogen, and
this approach may not model host-pathogen interactions in human TB faithfully *(37)*.

In support of a protective role for type I interferons, adjunctive interferon alpha therapy in addition to
conventional anti-tuberculous antibiotic treatment led to symptomatic and radiological improvement,
with a reduction in bacterial burden in respiratory tract samples, in small-scale human studies *(38–*
40). In keeping with this, an early peripheral blood type I interferon-inducible gene signature predicts
successful BCG-induced protection of macaques from subsequent Mtb challenge *(41)*. Type I
interferon mediated restriction of mycobacterial growth in in vitro granulomas comprising collagen
impregnated microspheres containing Mtb infected human peripheral blood mononuclear cells
(PBMC) *(42)* also suggests that type I interferon responses benefit the host.

Our observation of reduced recruitment of macrophages to the site of disease is likely the most
important factor driving increased susceptibility to *M. marinum* infection in *stat2* CRISPants.
Although macrophages have been implicated in the dissemination of *M. marinum* in zebrafish larvae
(20, 43), reduction of total macrophage numbers, impaired macrophage migration to the site of
mycobacterial infection or failure to control intracellular bacterial growth within macrophages have
all been associated with poor outcome *(20–22, 44, 45)*. In contrast, increasing macrophage numbers
via augmentation of M-CSF signalling either pre- or post-granuloma formation, promotes resistance
to *M. marinum* infection by reducing granuloma necrosis, with consequent curtailment of
extracellular mycobacterial growth *(21)*. The recent report that human genetically inherited CCR2
deficiency is associated with reduced pulmonary recruitment of monocytes, resulting in depleted
numbers of functionally normal alveolar macrophages and increased susceptibility to mycobacteria,
is also consistent with the notion that adequate numbers of macrophages are important for protective
anti-mycobacterial immunity *(46)*.

The reduction in neutrophils present at the site of *M. marinum* infection in *stat2* CRISPants may have
arisen due to baseline neutropenia, defective migration or both combined. On the basis that steady
state neutropenia did not affect the timing and magnitude of peak neutrophil recruitment to sterile
injury, impaired migration is probably the main driver of this phenotype, which likely also contributed
to increased severity of mycobacterial disease. Previous data show that reduced access of
neutrophils to mycobacteria leads to increased bacterial burden in a zebrafish line in which
neutrophils express mutant *cxcr4*, resulting in peripheral neutropenia and impaired neutrophil
recruitment to sites of inflammation, due to their retention in haematopoietic tissue *(23, 47)*.

Our study has some limitations. We were not able to address the reasons for variation in type I
interferon activity in our human cohort. Serum samples for measurement of autoantibodies to type I
interferons are not available and our sample size is insufficient for robust detection of associations
between genetic variation and the expression levels of type I interferon signalling pathway genes.
We were also unable to completely disentangle whether reduced neutrophil recruitment to the site
of *M. marinum* infection was a consequence of neutropenia or impaired migration. We have not

determined the mechanism by which attenuated type I interferon signalling leads to reduced myeloid
cell recruitment to *M. marinum*. The expression of several chemokines is type I interferon inducible
(25, 48, 49) and the CCR2-CCL2 and CXCR3-CXCL11 chemokine axes are known to be involved
in macrophage recruitment to *M. marinum (43, 50)*. Future studies are required to test the hypothesis
that *stat2* mutagenesis disrupts chemokine-mediated cellular recruitment to the site of mycobacterial
disease. Nonetheless, our work provides new insights into type I interferon mediated host protection
against mycobacterial infection.

Variation in type I interferon responses may arise due to genetically or epigenetically encoded
variation in the immune response to Mtb, neutralising type I interferon auto-antibodies, burden and
virulence of the mycobacterial inoculum and stochasticity in the immune response pathway following
exposure *(51–55)*. A central tenet of all these possibilities is that differences in the host immune
response to Mtb lead to differences in disease severity. Our findings have potential implications for
risk stratification of individuals in whom any of these mechanisms predisposing to low type I
interferon activity are identified. In active TB, such individuals could be targeted for longer or more
intensive drug regimens, or adjunctive type I interferon therapy delivered to the respiratory tract, to
mitigate against severe disease. Early intervention with type I interferon treatment, before destruction
of the lung parenchyma, is likely to be crucial to augment macrophage containment of Mtb, but timing
and duration of therapy will require evaluation in relatively large-scale experimental medicine trials.

MATERIALS AND METHODS

Ethics statement

The study was approved by the London Bloomsbury Research Ethics Committee (16/LO/0776).
Written informed consent was obtained from all participants.

Study design

We aimed to identify master regulators of human immune responses that correlate with severity of
TB disease, using transcriptional profiling of biopsies from the TST as a surrogate for immune
responses to TB in the lung and to test causation for observed associations by genetic manipulation
of identified upstream regulator molecules in the zebrafish larval mycobacterial infection model. To
encompass a broad spectrum of disease severity we recruited 51 adults (>18 years) from four
London hospitals, newly diagnosed with smear or culture positive pulmonary TB, who were within
four weeks of starting treatment. This is in keeping with the median sample size of previous studies
which have successfully demonstrated a relationship between severity of TB disease and
immunological parameters *(29, 56–59)*. Individuals with coincident human immunodeficiency virus
infection, malignancy, taking immunomodulatory therapy, a history of immunization within the
preceding two weeks or previous keloid formation, or unable to give informed consent were
excluded. Study participants underwent intradermal injection of 0.1 ml of two units of tuberculin (AJ
Vaccines) or saline in the volar aspect of the forearm as previously described *(4, 5, 8)*. At 48 hours
clinical induration at the injection site was measured, immediately prior to sampling by 3mm punch
biopsy as previously described *(4, 5)*. Additional saline samples from individuals with cured or latent
TB, BCG vaccine recipients and healthy volunteers have been described previously *(8)*.

RNA purification from skin biopsy and zebrafish embryo samples

Skin biopsies were homogenized as previously described *(8)*. Pooled zebrafish embryos (25-30 per
experimental condition) collected in Qiazol (Qiagen) were homogenized in CK14 lysing kit tubes
(Bertin Instruments) using a Precellys Evolution homogenizer (Bertin Instruments) for 10-20 seconds
at 5500 rpm. Total RNA from skin biopsies and zebrafish samples was purified using the RNEasy
mini and micro kits (Qiagen), respectively, according to the manufacturer's instructions. Genomic
DNA was removed using the TURBO DNA-free kit (ThermoFisher).

Transcriptional profiling of skin biopsy and zebrafish larval samples

Genome-wide mRNA sequencing was performed as previously described *(8, 60)*. Complementary
DNA (cDNA) libraries were prepared using the KAPA HyperPrep kit (Roche). Sequencing was
performed in paired-end mode with the NextSeq 500 High Output 75 Cycle Kit (Illumina) using the
NextSeq500 system (Illumina) according to the manufacturer's instructions, generating a median of
22 million (range 12.3-27.9 million) 41 base pair reads per human sample and 16.8 million (range

15.1-18.1 million) reads per zebrafish sample. Transcript alignment and quantitation against the
Ensembl GRCh38 human genome assembly release 100 or GRCz11 zebrafish genome assembly
release 104 was performed using Kallisto *(61)*. Transcript-level output counts and transcripts per
million (TPM) values were summed on gene level and annotated with Ensembl gene ID, gene name,
and gene biotype using the R/Bioconductor packages tximport and BiomaRt *(62, 63)*. Downstream
analysis was performed using R 3.6.3 on log2 transformed TPM values for protein-coding genes
only. TPM values <0.001 were set to 0.001 prior to log2 transformation. To determine the need for
and effect of batch correction in the human data, principal component analysis (PCA) was performed
using the prcomp R function on the integrated list of 6802 genes with the 10% lowest variance in
expression for each library preparation date. This revealed separation of three samples in PC1, likely
accounted for by lower RNA concentrations or RIN values compared to the rest of the dataset (Fig.
S1A). After batch correction performed using the ComBat function of the sva R package *(64)*,
allocating samples with PC1 score <0 and >0 to separate batches, this was no longer evident (Fig.
S1B).

Radiographic quantitation of TB severity

321 Disease severity was evaluated by estimating the extent of radiographic abnormalities and whether
322 cavitation was present on chest x-ray at the time of diagnosis, as previously described *(8, 9)*.

Outlier analysis

The BioBase Bioconductor R package was used to perform outlier analysis based on the z-score
outlier detection (ZODET) algorithm *(10)*, to identify transcripts in each TST sample whose
expression was significantly higher than the mean expression in control saline samples (>2SD,
p value <0.05), with a fold difference filter of >1 log2. Chi-squared tests implemented in R were then
used to identify outlier genes statistically enriched in TST samples compared to saline samples,
using a p value <0.05. To avoid type 2 error no correction for multiple testing was used in this
analysis. In instances where multiple Ensembl gene IDs were associated with a single gene symbol,
duplicate gene symbols were removed to retain the replicate with the highest expression for each
sample.

Pathway enrichment analysis

334 The biological pathways represented by the TST transcriptome were identified by Reactome
335 pathway enrichment analysis using XGR as previously described *(65, 66)*. For visualization, 15
336 pathway groups were identified by hierarchical clustering of Jaccard indices to quantify similarity
337 between the gene compositions of each pathway. For each group the pathway term with the largest
338 number of annotated genes was then selected as representative of enriched biology.

Upstream regulator analysis

TST transcriptome genes whose expression was significantly correlated with radiographic severity
of TB disease were identified by Spearman rank correlation, p value <0.05, without correction for
multiple testing, to prevent type 2 error. Genes positively and negatively correlated with disease
severity were separately subjected to Ingenuity Pathway Analysis (Qiagen) to identify upstream
molecules responsible for their transcriptional regulation. This analysis was restricted to molecules
annotated with the following functions: cytokine, transmembrane receptor, kinase and transcriptional
regulator, representing the canonical components of pathways which mediate transcriptional
reprogramming in immune responses. Enriched molecules with an adjusted p value <0.05 were
considered statistically significant.

Upstream regulator functional modules

TST gene modules representing the functional activity of their upstream molecule were identified as
previously described *(11)*. In brief, we calculated the average correlation coefficient for pairwise
correlations of the expression levels of the target genes associated with each predicted upstream
regulator. We compared these to the distribution of average correlation coefficients obtained from
100 iterations of randomly selecting equivalent sized groups of genes from the TST transcriptome.
Only target gene modules with average correlation coefficients higher than the mean of the
distribution of equivalent sized randomly selected groups by ≥2 SD (Z score ≥2) with false discovery
rate <0.05, were retained. We visualised these upstream regulator modules as network diagrams

using the Force Atlas two algorithm in Gephi v0.9.2 *(67)*, depicting all statistically over-represented
molecules (false discovery rate <0.05) predicted to be upstream of ≥4 target genes.

Transcriptional modules

Interferon inducible transcriptional module gene lists are provided in Table S1. Independently derived
human type I and type II interferon inducible gene modules were described previously *(5, 8, 11)*.
Two further modules were derived to distinguish type I or type II interferon inducible gene expression
using published transcriptional data for primary human keratinocytes stimulated with a selection of
cytokines (Gene Expression Omnibus accession: GSE36287) *(68)*. Stimulus-specific modules for
type I interferon (interferon alpha) and type II interferon (interferon gamma) were derived by selecting
genes overexpressed >4-fold in the cognate cytokine condition relative to all non-cognate conditions
combined (paired t test with α of p<0.05 without multiple testing correction), excluding genes also
induced by each non-cognate cytokine condition, using the same criteria. The babelgene R package
(https://igordot.github.io/babelgene/) was used to convert human gene symbols to their respective
zebrafish orthologues to generate the zebrafish Stat1 module, excluding zebrafish genes reported
to be an orthologue of more than one human gene. The zebrafish type I interferon inducible gene
module comprises 360 genes whose expression was significantly induced (≥2 fold, adjusted p value
<0.05) six hours after intravenous injection of three day post-fertilisation (dpf) larvae with 1 nl of
recombinant interferon phi 1 protein (1 mg/ml) as previously described *(16)*.

Venn diagrams

377 Area-proportional Venn diagrams visualizing the overlap between constituent genes in
378 transcriptional modules were generated using BioVenn *(69)*.

Zebrafish husbandry

Zebrafish were raised and maintained at 28.5°C following a 14/10 light/dark cycle according to
standard protocols *(70)* in University College London (UCL) and Neuro-PSI Zebrafish Facilities. All
work was approved by the British Home Office (Project License PP8780756) and the French Ministry
for Research and Higher Education (Project Licence 39238). All experiments were performed in
accordance with the relevant guidelines and regulations, on larvae up to five days post-fertilisation,
before they are protected under the Animals (Scientific Procedures) Act. Adult zebrafish were
spawned to collect embryos for experiments. Table S2 lists the lines used in this study *(26, 71, 72)*.
Embryos were maintained at 28.5°C in egg water containing 60 µg/ml Tropic Marin Sea Salt
(Norwood Aquarium) and anaesthetised with egg water containing 200 µg/ml buffered tricaine (3-
aminobenzoic acid ethyl ester) (Sigma-Aldrich) during injection, tail fin transection and imaging.
Larvae used for in vivo imaging were maintained in egg water supplemented at 24 hours post-
fertilisation (hpf) with 0.003% PTU (1-phenyl-2-thiourea) (Sigma-Aldrich) to inhibit melanisation.

CRISPant Generation

To maximise the likelihood of loss of functional protein we employed a previously described triple-
exon targeting approach *(73)*, with the modification that Cas9 protein was not diluted before use.
CRISPR RNA (crRNA) (Alt-R CRISPR-Cas9 crRNA), tracrRNA (Alt-R CRISPR-Cas9 tracrRNA) and
recombinant Cas9 protein (Alt-R Streptococcus pyogenes Cas9 Nuclease V3) were obtained from
Integrated DNA Technologies (IDT). Three pre-designed crRNAs targeting distinct exons were
selected for the *stat2* gene, prioritizing those that targeted early, asymmetric (not divisible by three)
exons common to both protein-coding transcripts, with low off-target and high on-target scores and
in a genomic position which allowed design of primers flanking the target site to generate a ~200 bp
amplicon, for verification of mutagenesis by next generation sequencing (MiSeq). crRNA sequences
and genomic locations are provided in Table S3. To generate gRNAs equal volumes of crRNA and
tracrRNA diluted to 61 µM in Duplex buffer (IDT) were annealed at 95°C for 5 minutes. Equal
volumes of gRNA (61 µM) and Cas9 protein (61 µM) were incubated at 37°C for 5 minutes to
assemble separate 30.5 µM ribonucleoproteins (RNPs) for each target. Equal volumes of the three
RNPs were pooled, prior to injection giving a final concentration of 10.2 µM for each. Negative control
"scrambled" crRNAs computationally designed to be non-targeting (Alt-R CRISPRCas9 Negative
Control crRNA #1, #2, #3) were prepared and pooled as described above. 0.5 nl of pooled *stat2*
RNPs or scrambled RNPs was injected into the yolk sac of single-cell stage wild type or transgenic
zebrafish embryos before cell inflation as previously described *(73)*. After injections embryos were

9

411 transferred into sterile petri dishes with fresh egg water and maintained at 28.5°C to the appropriate
412 age for experiments, as described below.

Interferon phi 1 stimulation

Three dpf *stat2* CRISPant *Tg(mxa:mCherry)* larvae and scrambled RNP injected siblings were
injected in the coelomic cavity with 1 nl of recombinant zebrafish interferon phi 1 protein (1.25 mg/ml),
produced as previously described *(74)*. *stat2* and control CRISPants were shuffled so that injections
were performed blindly. Bovine serum albumin (BSA) (1.25 mg/ml) was injected as a control.
Interferon phi 1 and BSA solutions were supplemented with 0.2% phenol red (Sigma-Aldrich) to
visualize the inoculum. Induction of Mxa reporter expression was determined by fluorescence
microscopy 24 hours post-injection.

M. marinum infection

M. marinum M strain expressing the pmsp12 mWasabi *(75)* or psMT3 mCherry plasmid *(76)* was
cultured using Middlebrook 7H10 agar (Becton Dickinson and Company) supplemented with 0.5%
oleic acid/albumin/dextrose/catalase (OADC) (Becton Dickinson and Company), 0.5% glycerol
(Sigma-Aldrich) and hygromycin (50 µg/ml) (Fisher Scientific). To generate bacterial suspensions for
injection, *M. marinum* from agar plates was cultured statically at 28.5°C for 24-36 hours in 10 ml
Middlebrook 7H9 broth (Becton Dickinson and Company) supplemented with 10%
albumin/dextrose/catalase (ADC) (Becton Dickinson and Company) and hygromycin (50 µg/ml)
(Fisher Scientific). Bacteria were harvested at mid-log growth (optical density (OD)600nm 0.7–1),
(OD)600nm 1 representing 10^8 colony forming units (cfu)/ml, washed three times in phosphate
buffered saline (PBS) (Gibco) and resuspended in 2% polyvinylpyrrolidone (PVP)40 (Sigma-
Aldrich)/PBS containing 10% phenol red (Sigma-Aldrich) to aid visualisation of injections *(77)*.

Zebrafish embryos were manually dechorionated using jeweller's forceps (Dumont #5, World
Precision Instruments) prior to bacterial infection. To generate systemic infection, 400 cfu
M. marinum in a volume of 1 nl were microinjected into the caudal vein of embryos staged at
28-30 hpf. Four days post-infection, embryos were either subjected to fluorescence microscopy to
measure disease severity or 25-30 per condition pooled and harvested in Qiazol (Qiagen) for
evaluation of immune responses by RNAseq. To generate localised infection, 200 cfu *M. marinum*
in a volume of 1 nl were injected into the hindbrain ventricle (HBV) of two dpf zebrafish larvae.
Cellular recruitment was evaluated by fluorescence microscopy at 6-18 hours post-infection.

Tailfin transection

Tailfin transections were performed as described previously *(26, 78)*. Briefly, live anaesthetised three
dpf zebrafish larvae were transferred with a 1 ml Pasteur pipette (Scientific Laboratory Supplies) to
a sterile petri dish containing 2% agarose (Bioline). Transections of the caudal fin were performed
using a sterile microscalpel (World Precision Instruments) by applying steady downward pressure to
create the incision at the boundary with the notochord. Following injury, larvae were rinsed in egg
water, and maintained in individual wells of a 96-well tissue culture plate (TPP) at 28.5°C until live
imaging to quantify neutrophil or macrophage recruitment to the site of injury at 1, 6 and 24 hours-
post-wound (hpw).

Fluorescence microscopy

All fluorescence microscopy was performed on live, anasethised larvae. For quantitation of bacterial
burden and dissemination four days post-infection, steady state neutrophil numbers at two dpf and
cellular recruitment at 2-4 dpf, larvae were imaged using an M205FA stereofluorescence microscope
(Leica) with a 1x objective. Larvae were imaged on a flat 1% agarose plate for quantitation of severity
of mycobacterial infection and steady state neutrophil numbers and a 96-well tissue culture plate
(TPP) in which the wells were coated with 1% agarose, for cellular recruitment to tailfin transection.
Micro-wells were created in 1% agarose using a Stampwell Larvae 1 device (Idylle) for optimal
positioning of 2-3 dpf larvae for imaging of cellular recruitment to hindbrain ventricle *M. marinum*
infection. Brightfield and fluorescence images were captured using a DFC365 FX camera (Leica)
and exported as 16-bit Tagged Image Format (TIF) files for analysis. For quantitation of steady state
macrophage numbers three dpf larvae were imaged in 96-well alignment plates (Funakoshi)
containing 75 µl egg water per well using a high-content wide-field fluorescence microscope
(Hermes, IDEA Bio-Medical) with a 4x objective, capturing five z planes 50.6 µm apart in four

contiguous fields of view per embryo. We created an ImageJ macro to semi-automate generation of
single maximum intensity projection z-stack montages from the Hermes images, which were saved
as 16-bit TIF files for analysis (Table S4. Mxa reporter expression was recorded with an EVOS
M7000 microscope (ThermoFisher) equipped with a 2x/NA0.06 objective and Texas Red
fluorescence cube. Larvae were positioned laterally in micro-wells created in 2% agarose with an in-
house-printed stamp. A single fluorescence plane was recorded as the depth of field is sufficient to
capture the entire larva. Transmitted light images were also recorded and both were exported as 16-
bit TIF files.

Image analysis

To quantify bacterial burden, number of bacterial foci and spatial distribution of bacteria, images
were analysed using custom QuantiFish software, previously developed in our group, to enable rapid
quantitation of fluorescent foci in zebrafish larvae *(79)*. Mxa reporter fluorescence was measured
with ImageJ. Transmitted and fluorescence images were stacked. Images were slightly rotated to
horizontality where necessary. A 600x100 pixel rectangular region of interest was defined on the
transmitted light image to encompass the entire gut and liver areas. Mean fluorescence intensity was
then measured on the fluorescence image. For quantitation of total cell number and recruitment of
fluorescent immune cells to the site of tailfin transection we developed a new custom Python script
which enables quantitation of integrated fluorescence within concentric zones (known as Sholl
circles) *(80)*. To achieve this, the script leverages the OpenCV, NumPy *(81)*, Matplotlib, SciPy
(http://www.scipy.org), scikit-image *(82)* and pandas Python libraries to facilitate image processing
and data extraction (Table S5. First the user is prompted to select a folder containing images for
analysis, as well as the file extensions corresponding to the brightfield and fluorescence images,
which are essential for the subsequent steps. The script then iterates through each pair of brightfield
and fluorescent images prompting the user to define two points on the brightfield image, which serve
as the start and end positions between which to create concentric circular regions *(80)* on the
corresponding fluorescence image. The script employs the image processing techniques described
in Table S5 to quantify integrated fluorescence of the entire image and that within each region, as a
surrogates for the total number of immune cells and the number at each spatial location, respectively
and generates output files containing this information. Integrated fluorescence within the first zone
(the wound site) and distance from the site of tailfin transection of the zone in which the maximal
integrated fluorescence (a surrogate for the highest cell numbers) was detected (identified manually)
were used as measures of immune cell recruitment for each zebrafish larva. The number of cells
recruited to the site of hindbrain *M. marinum* infection was quantified by manual counting.

Genotyping by next generation sequencing

Genomic DNA extraction

499 Genomic DNA was extracted from anasethetised individual zebrafish larvae using the modified hot
500 sodium hydroxide and Tris (HotSHOT) method as previously described *(73, 83)*. Briefly, larvae in
501 96-well plates were incubated in 50 µl base solution (25 mM KOH, 0.2 mM EDTA in water) at 95°C
502 for 30 min then cooled to room temperature, before addition of 50 µl neutralization solution (40 mM
503 Tris-HCL in water).

PCR

Extracted DNA (2 µl per 50 µl reaction) was subjected to PCR using Phusion High-Fidelity DNA
Polymerase (New England Biolabs) (98°C for 30 seconds (s), once only, 40 cycles of 98°C for 10 s,
59°C for 30 s, 72°C for 20 s, 72°C for 10 minutes, once only). Sequences and genomic positions of
the primers used are provided in Table S3. Successful amplification of a single product of
approximately 300 bp was verified by 2% agarose (Bioline) Tris-borate-EDTA (TBE) containing
Redsafe (Chembio) gel electrophoresis. PCR products were purified using ExoSAP-IT Express
(ThermoFisher), concentration of purified DNA determined by Nanodrop spectrophotometer
(ThermoFisher) and samples diluted to 15-25 ng/µl for sequencing.

Next generation sequencing and data analysis

Sequencing was performed by the UCL Fish Genomic Service using the MiSeq Reagent Kit v2 (300-
cycles) (Illumina) and the MiSeq system (Illumina) in paired end mode, according to the
manufacturer's instructions. Sequencing data were received as two FASTQ files (forward and

reverse) for each sample. Visual sequence analysis was performed using Geneious 10.2.6
(https://www.geneious.com) for initial verification of successful genome editing close to the PAM site.
Objective quantitation of the proportion of reads mutated and predicted to be frameshifted was
achieved using the ampliCan R package *(84)*, which utilizes the FASTQ files and a metadata file
providing the amplicon, protospacer adjacent motif (PAM) and primer sequences (Table S3) and
sample information, as previously described *(73)*. AmpliCan was run with default parameters, with
the exception that min_freq = 0.005 (mutations at a frequency below this threshold were considered
a sequencing error) and average_quality = 25. Mutations present in uninjected or scrambled RNP
injected control samples were not included as Cas9 induced mutations.

Statistical analysis

Statistical analysis was performed using GraphPad Prism 9.3.1 for Windows (GraphPad Software)
and R3.6.3. Chi-squared tests were used to identify outlier genes statistically enriched in
transcriptomic data from TST samples compared to saline samples, with no correction for multiple
testing to avoid type 2 error. Spearman rank correlation was used to determine the strength of
relationship between TST transcriptome gene expression and TB disease severity (two-tailed),
transcript levels of upstream regulator target gene modules and TST random gene modules (one-
tailed, positive correlation only) and mean expression of transcriptional modules in TST
transcriptomic data with severity of TB disease (two-tailed). The Benjamini-Hochberg correction
method for multiple comparisons was used to identify upstream regulator target gene modules with
average correlation coefficients significantly higher than the mean of the distribution of equivalent
sized randomly selected gene modules by ≥2 SD (Z score ≥2) with false discovery rate <0.05.
Survival of *stat2* CRISPant and control zebrafish larvae was compared using a log-rank (Mantel-
Cox) test; a p value <0.05 was considered significant. On scatter plots horizontal lines represent
median values and error bars indicate the interquartile range. On box and whisker plots horizontal
lines represent median values, box limits indicate the interquartile range and whiskers extend
between the 5th and 95th percentiles of the data. Two-tailed Mann-Whitney tests were used for two
group comparisons of unpaired data; a p value <0.05 was considered significant. Where p values
are not presented on graphs, * denotes p<0.05.

REFERENCES AND NOTES

1. A. K. Coussens, S. M. A. Zaidi, B. W. Allwood, P. K. Dewan, G. Gray, M. Kohli, T. Kredo, B. J.
Marais, G. B. Marks, L. Martinez, M. Ruhwald, T. J. Scriba, J. A. Seddon, P. Tisile, D. F. Warner, R.
J. Wilkinson, H. Esmail, R. M. G. J. Houben, International Consensus for Early TB (ICE-TB) group,
Classification of early tuberculosis states to guide research for improved care and prevention: an
international Delphi consensus exercise. *Lancet Respir. Med.* **12**, 484–498 (2024).

2. A. M. Cadena, S. M. Fortune, J. L. Flynn, Heterogeneity in tuberculosis. *Nat. Rev. Immunol.* **17**,
691–702 (2017).

3. S. H. E. Kaufmann, C. Lange, M. Rao, K. N. Balaji, M. Lotze, M. Schito, A. I. Zumla, M. Maeurer,
Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review.
Lancet Respir. Med. **2**, 301–320 (2014).

4. G. S. Tomlinson, T. J. Cashmore, P. T. G. Elkington, J. Yates, R. J. Lehloenya, J. Tsang, M.
Brown, R. F. Miller, K. Dheda, D. R. Katz, B. M. Chain, M. Noursadeghi, Transcriptional profiling of
innate and adaptive human immune responses to mycobacteria in the tuberculin skin test. *Eur. J.
Immunol.* **41**, 3253–3260 (2011).

5. L. C. K. Bell, G. Pollara, M. Pascoe, G. S. Tomlinson, R. J. Lehloenya, J. Roe, R. Meldau, R. F.
Miller, A. Ramsay, B. M. Chain, K. Dheda, M. Noursadeghi, In Vivo Molecular Dissection of the
Effects of HIV-1 in Active Tuberculosis. *PLoS Pathog.* **12**, e1005469 (2016).

6. M.-J. Kim, H. C. Wainwright, M. Locketz, L.-G. Bekker, G. B. Walther, C. Dittrich, A. Visser, W.
Wang, F.-F. Hsu, U. Wiehart, L. Tsenova, G. Kaplan, D. G. Russell, Caseation of human tuberculosis
granulomas correlates with elevated host lipid metabolism. *EMBO Mol. Med.* **2**, 258–274 (2010).

7. L. Ramakrishnan, The zebrafish guide to tuberculosis immunity and treatment. *Cold Spring Harb.*

Symp. Quant. Biol. **78**, 179–192 (2013).

8. G. Pollara, C. T. Turner, J. Rosenheim, A. Chandran, L. C. K. Bell, A. Khan, A. Patel, L. F. Peralta, A. Folino, A. Akarca, C. Venturini, T. Baker, S. Ecker, F. L. M. Ricciardolo, T. Marafioti, C. Ugarte-Gil, D. A. J. Moore, B. M. Chain, G. S. Tomlinson, M. Noursadeghi, Exaggerated IL-17A activity in human in vivo recall responses discriminates active tuberculosis from latent infection and cured disease. *Sci. Transl. Med.* **13**, eabg7673 (2021).

9. A. P. Ralph, M. Ardian, A. Wiguna, G. P. Maguire, N. G. Becker, G. Drogumuller, M. J. Wilks, G. Waramori, E. Tjitra, null Sandjaja, E. Kenagalem, G. J. Pontororing, N. M. Anstey, P. M. Kelly, A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis. *Thorax* **65**, 863–869 (2010).

10. D. L. Roden, G. W. Sewell, A. Lobley, A. P. Levine, A. M. Smith, A. W. Segal, ZODET: software for the identification, analysis and visualisation of outlier genes in microarray expression data. *PloS One* **9**, e81123 (2014).

11. A. Chandran, J. Rosenheim, G. Nageswaran, L. Swadling, G. Pollara, R. K. Gupta, A. R. Burton, J. A. Guerra-Assunção, A. Woolston, T. Ronel, C. Pade, J. M. Gibbons, B. Sanz-Magallon Duque De Estrada, M. Robert de Massy, M. Whelan, A. Semper, T. Brooks, D. M. Altmann, R. J. Boyton, Á. McKnight, G. Captur, C. Manisty, T. A. Treibel, J. C. Moon, G. S. Tomlinson, M. K. Maini, B. M. Chain, M. Noursadeghi, COVIDsortium Investigators, Rapid synchronous type 1 IFN and virus-specific T cell responses characterize first wave non-severe SARS-CoV-2 infections. *Cell Rep. Med.* **3**, 100557 (2022).

12. R. L. Kinsella, D. X. Zhu, G. A. Harrison, A. E. Mayer Bridwell, J. Prusa, S. M. Chavez, C. L. Stallings, Perspectives and Advances in the Understanding of Tuberculosis. *Annu. Rev. Pathol. Mech. Dis.* **16**, 377–408 (2021).

13. F. Paduano, E. Gaudio, A. A. Mensah, S. Pinton, F. Bertoni, F. Trapasso, T-Cell Leukemia/Lymphoma 1 (TCL1): An Oncogene Regulating Multiple Signaling Pathways. *Front. Oncol.* **8**, 317 (2018).

14. F. McNab, K. Mayer-Barber, A. Sher, A. Wack, A. O'Garra, Type I interferons in infectious disease. *Nat. Rev. Immunol.* **15**, 87–103 (2015).

15. C. Langevin, E. Aleksejeva, G. Passoni, N. Palha, J.-P. Levraud, P. Boudinot, The antiviral innate immune response in fish: evolution and conservation of the IFN system. *J. Mol. Biol.* **425**, 4904–4920 (2013).

16. J.-P. Levraud, L. Jouneau, V. Briolat, V. Laghi, P. Boudinot, IFN-Stimulated Genes in Zebrafish and Humans Define an Ancient Arsenal of Antiviral Immunity. *J. Immunol. Baltim. Md 1950* **203**, 3361–3373 (2019).

17. K. Blaszczyk, H. Nowicka, K. Kostyrko, A. Antonczyk, J. Wesoly, H. A. R. Bluyssen, The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses. *Cytokine Growth Factor Rev.* **29**, 71–81 (2016).

18. A. Begitt, M. Droescher, T. Meyer, C. D. Schmid, M. Baker, F. Antunes, K.-P. Knobeloch, M. R. Owen, R. Naumann, T. Decker, U. Vinkemeier, STAT1-cooperative DNA binding distinguishes type 1 from type 2 interferon signaling. *Nat. Immunol.* **15**, 168–176 (2014).

19. J. W. Schoggins, Interferon-Stimulated Genes: What Do They All Do? *Annu. Rev. Virol.* **6**, 567–584 (2019).

20. H. Clay, J. M. Davis, D. Beery, A. Huttenlocher, S. E. Lyons, L. Ramakrishnan, Dichotomous role of the macrophage in early Mycobacterium marinum infection of the zebrafish. *Cell Host Microbe* **2**, 29–39 (2007).

13

21. A. J. Pagán, C.-T. Yang, J. Cameron, L. E. Swaim, F. Ellett, G. J. Lieschke, L. Ramakrishnan,
Myeloid Growth Factors Promote Resistance to Mycobacterial Infection by Curtailing Granuloma
Necrosis through Macrophage Replenishment. *Cell Host Microbe* **18**, 15–26 (2015).

22. R. D. Berg, S. Levitte, M. P. O'Sullivan, S. M. O'Leary, C. J. Cambier, J. Cameron, K. K. Takaki,
C. B. Moens, D. M. Tobin, J. Keane, L. Ramakrishnan, Lysosomal Disorders Drive Susceptibility to
Tuberculosis by Compromising Macrophage Migration. *Cell* **165**, 139–152 (2016).

23. C.-T. Yang, C. J. Cambier, J. M. Davis, C. J. Hall, P. S. Crosier, L. Ramakrishnan, Neutrophils
exert protection in the early tuberculous granuloma by oxidative killing of mycobacteria
phagocytosed from infected macrophages. *Cell Host Microbe* **12**, 301–312 (2012).

24. P. M. Elks, S. Brizee, M. van der Vaart, S. R. Walmsley, F. J. van Eeden, S. A. Renshaw, A. H.
Meijer, Hypoxia inducible factor signaling modulates susceptibility to mycobacterial infection via a
nitric oxide dependent mechanism. *PLoS Pathog.* **9**, e1003789 (2013).

25. I. Rauch, M. Müller, T. Decker, The regulation of inflammation by interferons and their STATs.
JAK-STAT **2**, e23820 (2013).

26. S. A. Renshaw, C. A. Loynes, D. M. I. Trushell, S. Elworthy, P. W. Ingham, M. K. B. Whyte, A
transgenic zebrafish model of neutrophilic inflammation. *Blood* **108**, 3976–3978 (2006).

27. C. Gray, C. A. Loynes, M. K. B. Whyte, D. C. Crossman, S. A. Renshaw, T. J. A. Chico,
Simultaneous intravital imaging of macrophage and neutrophil behaviour during inflammation using
a novel transgenic zebrafish. *Thromb. Haemost.* **105**, 811–819 (2011).

28. F. Ellett, L. Pase, J. W. Hayman, A. Andrianopoulos, G. J. Lieschke, mpeg1 promoter transgenes
direct macrophage-lineage expression in zebrafish. *Blood* **117**, e49-56 (2011).

29. M. P. R. Berry, C. M. Graham, F. W. McNab, Z. Xu, S. A. A. Bloch, T. Oni, K. A. Wilkinson, R.
Banchereau, J. Skinner, R. J. Wilkinson, C. Quinn, D. Blankenship, R. Dhawan, J. J. Cush, A. Mejias,
O. Ramilo, O. M. Kon, V. Pascual, J. Banchereau, D. Chaussabel, A. O'Garra, An interferon-
inducible neutrophil-driven blood transcriptional signature in human tuberculosis. *Nature* **466**, 973–
977 (2010).

30. C. I. Bloom, C. M. Graham, M. P. R. Berry, K. A. Wilkinson, T. Oni, F. Rozakeas, Z. Xu, J.
Rossello-Urgell, D. Chaussabel, J. Banchereau, V. Pascual, M. Lipman, R. J. Wilkinson, A. O'Garra,
Detectable Changes in The Blood Transcriptome Are Present after Two Weeks of Antituberculosis
Therapy. *PLOS ONE* **7**, e46191 (2012).

31. T. H. M. Ottenhoff, R. H. Dass, N. Yang, M. M. Zhang, H. E. E. Wong, E. Sahiratmadja, C. C.
Khor, B. Alisjahbana, R. van Crevel, S. Marzuki, M. Seielstad, E. van de Vosse, M. L. Hibberd,
Genome-Wide Expression Profiling Identifies Type 1 Interferon Response Pathways in Active
Tuberculosis. *PLOS ONE* **7**, e45839 (2012).

32. K. D. Mayer-Barber, B. B. Andrade, D. L. Barber, S. Hieny, C. G. Feng, P. Caspar, S. Oland, S.
Gordon, A. Sher, Innate and Adaptive Interferons Suppress IL-1α and IL-1β Production by Distinct
Pulmonary Myeloid Subsets during Mycobacterium tuberculosis Infection. *Immunity* **35**, 1023–1034
(2011).

33. K. D. Mayer-Barber, B. B. Andrade, S. D. Oland, E. P. Amaral, D. L. Barber, J. Gonzales, S. C.
Derrick, R. Shi, N. P. Kumar, W. Wei, X. Yuan, G. Zhang, Y. Cai, S. Babu, M. Catalfamo, A. M.
Salazar, L. E. Via, C. E. Barry, A. Sher, Host-directed therapy of tuberculosis based on interleukin-
1 and type I interferon crosstalk. *Nature* **511**, 99–103 (2014).

34. D. X. Ji, L. H. Yamashiro, K. J. Chen, N. Mukaida, I. Kramnik, K. H. Darwin, R. E. Vance, Type I
interferon-driven susceptibility to Mycobacterium tuberculosis is mediated by IL-1Ra. *Nat. Microbiol.*
4, 2128–2135 (2019).

35. D. I. Kotov, O. V. Lee, S. A. Fattinger, C. A. Langner, J. V. Guillen, J. M. Peters, A. Moon, E. M.
Burd, K. C. Witt, D. B. Stetson, D. L. Jaye, B. D. Bryson, R. E. Vance, Early cellular mechanisms of
type I interferon-driven susceptibility to tuberculosis. *Cell* **186**, 5536-5553.e22 (2023).

36. L. Moreira-Teixeira, K. Mayer-Barber, A. Sher, A. O'Garra, Type I interferons in tuberculosis: Foe
and occasionally friend. *J. Exp. Med.* **215**, 1273–1285 (2018).

37. I. Kramnik, G. Beamer, Mouse models of human TB pathology: roles in the analysis of necrosis
and the development of host-directed therapies. *Semin. Immunopathol.* **38**, 221–237 (2016).

38. S. Giosué, M. Casarini, L. Alemanno, G. Galluccio, P. Mattia, G. Pedicelli, L. Rebek, A. Bisetti,
F. Ameglio, Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis. *Am. J.*
Respir. Crit. Care Med. **158**, 1156–1162 (1998).

39. P. Zarogoulidis, I. Kioumis, N. Papanas, K. Manika, T. Kontakiotis, A. Papagianis, K.
Zarogoulidis, The effect of combination IFN-alpha-2a with usual antituberculosis chemotherapy in
non-responding tuberculosis and diabetes mellitus: a case report and review of the literature. *J.*
Chemother. **24**, 173–177 (2012).

40. D. Mansoori, S. Tavana, M. Mirsaeidi, M. Yazdanpanah, H. Sohrabpour, The Efficacy of
Interferon-α in the Treatment of Multidrug Resistant Tuberculosis. *TANAFFOS* **1**, 29–34 (2002).

41. Y. E. Liu, P. A. Darrah, J. J. Zeppa, M. Kamath, F. Laboune, D. C. Douek, P. Maiello, M.
Roederer, J. L. Flynn, R. A. Seder, P. Khatri, Blood transcriptional correlates of BCG-induced
protection against tuberculosis in rhesus macaques. *Cell Rep. Med.* **4**, 101096 (2023).

42. L. B. Tezera, M. K. Bielecka, A. Chancellor, M. T. Reichmann, B. A. Shammari, P. Brace, A.
Batty, A. Tocheva, S. Jogai, B. G. Marshall, M. Tebruegge, S. N. Jayasinghe, S. Mansour, P. T.
Elkington, B. Aldridge, Ed. Dissection of the host-pathogen interaction in human tuberculosis using
a bioengineered 3-dimensional model. *eLife* **6**, e21283 (2017).

43. V. Torraca, C. Cui, R. Boland, J.-P. Bebelman, A. M. van der Sar, M. J. Smit, M. Siderius, H. P.
Spaink, A. H. Meijer, The CXCR3-CXCL11 signaling axis mediates macrophage recruitment and
dissemination of mycobacterial infection. *Dis. Model. Mech.* **8**, 253–269 (2015).

44. J. M. Davis, H. Clay, J. L. Lewis, N. Ghori, P. Herbomel, L. Ramakrishnan, Real-time visualization
of mycobacterium-macrophage interactions leading to initiation of granuloma formation in zebrafish
embryos. *Immunity* **17**, 693–702 (2002).

45. D. M. Tobin, F. J. Roca, S. F. Oh, R. McFarland, T. W. Vickery, J. P. Ray, D. C. Ko, Y. Zou, N.
D. Bang, T. T. H. Chau, J. C. Vary, T. R. Hawn, S. J. Dunstan, J. J. Farrar, G. E. Thwaites, M.-C.
King, C. N. Serhan, L. Ramakrishnan, Host genotype-specific therapies can optimize the
inflammatory response to mycobacterial infections. *Cell* **148**, 434–446 (2012).

46. A.-L. Neehus, B. Carey, M. Landekic, P. Panikulam, G. Deutsch, M. Ogishi, C. A. Arango-Franco,
Q. Philippot, M. Modaresi, I. Mohammadzadeh, M. Corcini Berndt, D. Rinchai, T. Le Voyer, J. Rosain,
M. Momenilandi, M. Martin-Fernandez, T. Khan, J. Bohlen, J. E. Han, A. Deslys, M. Bernard, T.
Gajardo-Carrasco, C. Soudée, C. Le Floc'h, M. Migaud, Y. Seeleuthner, M.-S. Jang, E. Nikolouli, S.
Seyedpour, H. Begueret, J.-F. Emile, P. Le Guen, G. Tavazzi, C. N. J. Colombo, F. C. Marzani, M.
Angelini, F. Trespidi, S. Ghirardello, N. Alipour, A. Molitor, R. Carapito, M. Mazloomrezaei, H. Rokni-
Zadeh, M. Changi-Ashtiani, C. Brouzes, P. Vargas, A. Borghesi, N. Lachmann, S. Bahram, B.
Crestani, S. Pahari, L. S. Schlesinger, N. Marr, D. Bugonovic, S. Boisson-Dupuis, V. Béziat, L. Abel,
R. Borie, L. R. Young, R. Deterding, M. Shahrooei, N. Rezaei, N. Parvaneh, D. Craven, P. Gros, D.
Malo, F. E. Sepulveda, L. M. Nogee, N. Aladjidi, B. C. Trapnell, J.-L. Casanova, J. Bustamante,
Human inherited CCR2 deficiency underlies progressive polycystic lung disease. *Cell* **187**, 390-
408.e23 (2024).

47. K. B. Walters, J. M. Green, J. C. Surfus, S. K. Yoo, A. Huttenlocher, Live imaging of neutrophil

motility in a zebrafish model of WHIM syndrome. *Blood* **116**, 2803–2811 (2010).

48. M. H. Lehmann, L. E. Torres-Domínguez, P. J. R. Price, C. Brandmüller, C. J. Kirschning, G.
Sutter, CCL2 expression is mediated by type I IFN receptor and recruits NK and T cells to the lung
during MVA infection. *J. Leukoc. Biol.* **99**, 1057–1064 (2016).

49. M. Buttmann, C. Merzyn, P. Rieckmann, Interferon-beta induces transient systemic IP-
10/CXCL10 chemokine release in patients with multiple sclerosis. *J. Neuroimmunol.* **156**, 195–203
(2004).

50. C. J. Cambier, K. K. Takaki, R. P. Larson, R. E. Hernandez, D. M. Tobin, K. B. Urdahl, C. L.
Cosma, L. Ramakrishnan, Mycobacteria manipulate macrophage recruitment through coordinated
use of membrane lipids. *Nature* **505**, 218–222 (2014).

51. L. Abel, J. Fellay, D. W. Haas, E. Schurr, G. Srikrishna, M. Urbanowski, N. Chaturvedi, S.
Srinivasan, D. H. Johnson, W. R. Bishai, Genetics of human susceptibility to active and latent
tuberculosis: present knowledge and future perspectives. *Lancet Infect. Dis.* **18**, e64–e75 (2018).

52. A. Khadela, V. P. Chavda, H. Postwala, Y. Shah, P. Mistry, V. Apostolopoulos, Epigenetics in
Tuberculosis: Immunomodulation of Host Immune Response. *Vaccines* **10**, 1740 (2022).

53. A. L. Jacobs, Infective dose in pulmonary tuberculosis. *Tubercle* **22**, 266–271 (1941).

54. C. R. Plumlee, F. J. Duffy, B. H. Gern, J. L. Delahaye, S. B. Cohen, C. R. Stoltzfus, T. R. Rustad,
S. G. Hansen, M. K. Axthelm, L. J. Picker, J. D. Aitchison, D. R. Sherman, V. V. Ganusov, M. Y.
Gerner, D. E. Zak, K. B. Urdahl, Ultra-low Dose Aerosol Infection of Mice with Mycobacterium
tuberculosis More Closely Models Human Tuberculosis. *Cell Host Microbe* **29**, 68-82.e5 (2021).

55. J.-L. Casanova, M. S. Anderson, Unlocking life-threatening COVID-19 through two types of
inborn errors of type I IFNs. *J. Clin. Invest.* **133**, e166283.

56. P. Elkington, T. Shiomi, R. Breen, R. K. Nuttall, C. A. Ugarte-Gil, N. F. Walker, L. Saraiva, B.
Pedersen, F. Mauri, M. Lipman, D. R. Edwards, B. D. Robertson, J. D'Armiento, J. S. Friedland,
MMP-1 drives immunopathology in human tuberculosis and transgenic mice. *J. Clin. Invest.* **121**,
1827–1833 (2011).

57. L. Guglielmetti, A. Cazzadori, M. Conti, F. Boccafoglio, A. Vella, R. Ortolani, E. Concia,
Lymphocyte subpopulations in active tuberculosis: association with disease severity and the QFT-
GIT assay. *Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis.* **17**, 825–828 (2013).

58. J. O. Jurado, V. Pasquinelli, I. B. Alvarez, D. Peña, A. I. Rovetta, N. L. Tateosian, H. E. Romeo,
R. M. Musella, D. Palmero, H. E. Chuluyán, V. E. García, IL-17 and IFN-γ expression in lymphocytes
from patients with active tuberculosis correlates with the severity of the disease. *J. Leukoc. Biol.* **91**,
991–1002 (2012).

59. Z. Hasan, B. Jamil, J. Khan, R. Ali, M. A. Khan, N. Nasir, M. S. Yusuf, S. Jamil, M. Irfan, R.
Hussain, Relationship between circulating levels of IFN-gamma, IL-10, CXCL9 and CCL2 in
pulmonary and extrapulmonary tuberculosis is dependent on disease severity. *Scand. J. Immunol.*
69, 259–267 (2009).

60. J. Roe, C. Venturini, R. K. Gupta, C. Gurry, B. M. Chain, Y. Sun, J. Southern, C. Jackson, M. C.
Lipman, R. F. Miller, A. R. Martineau, I. Abubakar, M. Noursadeghi, Blood Transcriptomic
Stratification of Short-term Risk in Contacts of Tuberculosis. *Clin. Infect. Dis. Off. Publ. Infect. Dis.*
Soc. Am. **70**, 731–737 (2020).

61. N. L. Bray, H. Pimentel, P. Melsted, L. Pachter, Near-optimal probabilistic RNA-seq
quantification. *Nat. Biotechnol.* **34**, 525–527 (2016).

62. C. Soneson, M. I. Love, M. D. Robinson, Differential analyses for RNA-seq: transcript-level
estimates improve gene-level inferences. *F1000Research* **4**, 1521 (2015).

63. S. Durinck, P. T. Spellman, E. Birney, W. Huber, Mapping identifiers for the integration of
genomic datasets with the R/Bioconductor package biomaRt. *Nat. Protoc.* **4**, 1184–1191 (2009).

64. J. T. Leek, W. E. Johnson, H. S. Parker, A. E. Jaffe, J. D. Storey, The sva package for removing
batch effects and other unwanted variation in high-throughput experiments. *Bioinforma. Oxf. Engl.*
28, 882–883 (2012).

65. H. Fang, B. Knezevic, K. L. Burnham, J. C. Knight, XGR software for enhanced interpretation of
genomic summary data, illustrated by application to immunological traits. *Genome Med.* **8**, 129
(2016).

66. C. T. Turner, J. Brown, E. Shaw, I. Uddin, E. Tsaliki, J. K. Roe, G. Pollara, Y. Sun, J. M. Heather,
M. Lipman, B. Chain, M. Noursadeghi, Persistent T Cell Repertoire Perturbation and T Cell
Activation in HIV After Long Term Treatment. *Front. Immunol.* **12**, 634489 (2021).

67. M. Jacomy, T. Venturini, S. Heymann, M. Bastian, ForceAtlas2, a continuous graph layout
algorithm for handy network visualization designed for the Gephi software. *PloS One* **9**, e98679
(2014).

68. W. R. Swindell, X. Xing, P. E. Stuart, C. S. Chen, A. Aphale, R. P. Nair, J. J. Voorhees, J. T.
Elder, A. Johnston, J. E. Gudjonsson, Heterogeneity of inflammatory and cytokine networks in
chronic plaque psoriasis. *PloS One* **7**, e34594 (2012).

69. T. Hulsen, J. de Vlieg, W. Alkema, BioVenn - a web application for the comparison and
visualization of biological lists using area-proportional Venn diagrams. *BMC Genomics* **9**, 488 (2008).

70. C. Nusslein-Volhard, *Zebrafish: A Practical Approach* R. Dahm, Ed. (Oxford University Press,
Oxford, 1 edition., 2002).

71. G. Maarifi, N. Smith, S. Maillet, O. Moncorgé, C. Chamontin, J. Edouard, F. Sohm, F. P. Blanchet,
J.-P. Herbeuval, G. Lutfalla, J.-P. Levraud, N. J. Arhel, S. Nisole, TRIM8 is required for virus-induced
IFN response in human plasmacytoid dendritic cells. *Sci. Adv.* **5**, eaax3511 (2019).

72. K. Voelz, R. L. Gratacap, R. T. Wheeler, A zebrafish larval model reveals early tissue-specific
innate immune responses to Mucor circinelloides. *Dis. Model. Mech.* **8**, 1375–1388 (2015).

73. F. Kroll, G. T. Powell, M. Ghosh, G. Gestri, P. Antinucci, T. J. Hearn, H. Tunbak, S. Lim, H. W.
Dennis, J. M. Fernandez, D. Whitmore, E. Dreosti, S. W. Wilson, E. J. Hoffman, J. Rihel, S. C. Ekker,
D. Y. Stainier, D. Balciunas, Eds. A simple and effective F0 knockout method for rapid screening of
behaviour and other complex phenotypes. *eLife* **10**, e59683 (2021).

74. D. Aggad, M. Mazel, P. Boudinot, K. E. Mogensen, O. J. Hamming, R. Hartmann, S. Kotenko,
P. Herbomel, G. Lutfalla, J.-P. Levraud, The two groups of zebrafish virus-induced interferons signal
via distinct receptors with specific and shared chains. *J. Immunol. Baltim. Md 1950* **183**, 3924–3931
(2009).

75. K. Takaki, J. M. Davis, K. Winglee, L. Ramakrishnan, Evaluation of the pathogenesis and
treatment of Mycobacterium marinum infection in zebrafish. *Nat. Protoc.* **8**, 1114–1124 (2013).

76. L. M. van Leeuwen, M. van der Kuip, S. A. Youssef, A. de Bruin, W. Bitter, A. M. van Furth, A.
M. van der Sar, Modeling tuberculous meningitis in zebrafish using Mycobacterium marinum. *Dis.*
Model. Mech. **7**, 1111–1122 (2014).

77. E. L. Benard, A. M. van der Sar, F. Ellett, G. J. Lieschke, H. P. Spaink, A. H. Meijer, Infection of
zebrafish embryos with intracellular bacterial pathogens. *J. Vis. Exp. JoVE* (2012),

doi:10.3791/3781.

78. R. N. Wilkinson, S. Elworthy, P. W. Ingham, F. J. M. van Eeden, A method for high-throughput
PCR-based genotyping of larval zebrafish tail biopsies. *BioTechniques* **55**, 314–316 (2013).

79. D. R. Stirling, O. Suleyman, E. Gil, P. M. Elks, V. Torraca, M. Noursadeghi, G. S. Tomlinson,
Analysis tools to quantify dissemination of pathology in zebrafish larvae. *Sci. Rep.* **10**, 3149 (2020).

80. D. A. Sholl, Dendritic organization in the neurons of the visual and motor cortices of the cat. *J.*
Anat. **87**, 387–406 (1953).

81. S. van der Walt, S. C. Colbert, G. Varoquaux, The NumPy Array: A Structure for Efficient
Numerical Computation. *Comput. Sci. Eng.* **13**, 22–30 (2011).

82. S. van der Walt, J. L. Schönberger, J. Nunez-Iglesias, F. Boulogne, J. D. Warner, N. Yager, E.
Gouillart, T. Yu, scikit-image contributors, scikit-image: image processing in Python. *PeerJ* **2**, e453
(2014).

83. N. D. Meeker, S. A. Hutchinson, L. Ho, N. S. Trede, Method for isolation of PCR-ready genomic
DNA from zebrafish tissues. *BioTechniques* **43**, 610, 612, 614 (2007).

84. K. Labun, X. Guo, A. Chavez, G. Church, J. A. Gagnon, E. Valen, Accurate analysis of genuine
CRISPR editing events with ampliCan. *Genome Res.* **29**, 843–847 (2019).

ACKNOWLEDGEMENTS

We thank Michelle Berin and Victoria Dean (Clinical Research Nurses, UCL Division of Infection and
Immunity) and Mylah Ramirez (Research Nurse, Barts Health NHS Trust) for support with research
governance, participant recruitment and sample collection. We thank the UCL Zebrafish Facility staff,
particularly Heather Callaway, Jenna Hakkesteeg, Karen Dunford, Carole Wilson and Elise
Hitchcock for maintenance of the zebrafish lines used in this study, especially during the first wave
of the COVID-19 pandemic. We thank UCL Genomics for library preparation and sequencing of
samples for transcriptional profiling (www.ucl.ac.uk/child-health/research/genetics-and-genomic-
medicine/ucl-genomics). We thank Alex Lubin and Katie-Jo Miller for next generation sequencing of
zebrafish samples for genotyping. This work has benefited from the facilities and expertise of
CELPHEDIA-TEFOR, UAR2010 TEFOR Paris-Saclay (TEFOR Infrastructure - Investissement
d'avenir - ANR-II-INBS-0014) and from the Recombinant Protein Platform of the Institut Pasteur,
Paris.

FUNDING

UK Medical Research Council Clinician Scientist Fellowship MR/N007727/1 (GST)

Wellcome Trust Investigator Award 207511/Z/17/Z (MN)

Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society 105570/Z/14/Z
(PME)

Fondation pour la Recherche Medicale grant EQU202203014646 (J-PL)

National Institute of Health Research Biomedical Research Centre Funding to University College
Hospitals NHS Foundation Trust and University College London (GST, MN)

This research was funded in whole, or in part, by the Wellcome Trust [207511/Z/17/Z,
105570/Z/14/Z]. For the purpose of Open Access, the author has applied a CC BY public copyright
licence to any Author Accepted Manuscript version arising from this submission.

AUTHOR CONTRIBUTIONS

Conceived the study: GST, MN

Collected the data: ASS, BSMDDE, JR, ET, GP, J-PL, GST

Provided resources or analysis tools: ASS, BSMDDE, JR, CTT, MCIL, HK, GP, PME, EMP, J-PL,
MN, GST

Performed the data analysis / interpretation: ASS, BSMDDE, JR, CTT, GP, PME, EMP, J-PL, MN,
GST

Prepared the manuscript draft: GST, ASS, BSMDDE

All authors reviewed and contributed to the final manuscript.

COMPETING INTERESTS

The authors declare that they have no competing interests.

DATA AND MATERIALS AVAILABILITY

Human RNAseq data are already available in the ArrayExpress repository under accession number
E-MTAB-6816. Zebrafish RNAseq data will be made available in ArrayExpress at the time of peer
reviewed publication of the manuscript. The source code and manual for QuantiFish software used
for analysis of bacterial burden and dissemination in zebrafish larvae are available at
https://github.com/DavidStirling/QuantiFish. The ImageJ macro used to generate montages from the
Hermes images and source code and manual for the Python script used for analysis of steady state
cell numbers and cellular recruitment in zebrafish are available at
https://github.com/AndSzyShe/particle_analysis. Source data for figure panels with fewer than 20
data points are available in Data file S1.

FIGURES

Fig. 1. Reduced type I interferon activity in the TST transcriptome is associated with
increased severity of human TB disease. (A) Frequency distribution of the correlation coefficients
for the relationship between the abundance of each of the 3222 transcripts within the tuberculin skin
test (TST) transcriptome derived from 51 individuals with pulmonary tuberculosis (TB) and
radiographic disease severity. Coloured boxes highlight statistically significant correlations (p<0.05).
(B, C) Network diagrams of statistically significant (FDR<0.05) cytokines **(B)** and transcription factors
(C) predicted to be upstream regulators (red) of target gene modules (blue) whose expression is
negatively correlated with radiological TB severity. Size of the nodes for upstream regulators is
proportional to -Log10 p value. Nodes were clustered using the Force Atlas 2 algorithm in Gephi
(version 0.9.2). **(D, E)** The inverse relationship between average expression in each TST sample of
two distinct, independently derived gene modules representing type I interferon activity **(D)** with TB
severity **(E)**. r values and p values were derived from two-tailed Spearman rank correlations. CXR =
Chest x-ray, MΦ = Macrophage, KC = Keratinocyte.

867
868

Fig. 2. *M. marinum* **infection induces a type I interferon response in zebrafish larvae.**
(A) Schematic representation of the human canonical type I interferon signalling pathway (left) which
is highly conserved in zebrafish (right). **(B, C)** The average expression of two largely non-overlapping
(B) type I interferon inducible gene modules derived from independent data (Table S1) is elevated
in *M. marinum* (Mm) infected embryos (4 days post-intravenous infection) compared with uninfected
(UI) siblings **(C)**. Data are from four independent experiments.

880
Fig. 3. Increased severity of *M. marinum* infection in *stat2* CRISPants. (A) *stat2* CRISPant
(*stat2-/-*) and control ribonucleoprotein (RNP) injected (*stat2+/+*) zebrafish larvae four days post
intravenous infection with 400 colony forming units (cfu) mCherry-expressing *M. marinum*. Scale bar
= 250 μm. **(B)** Survival of control and *stat2* disrupted zebrafish larvae 1-4 days post infection with
M. marinum. p value was derived from a log-rank (Mantel-Cox) test. **(C-E)** Comparison of integrated
fluorescence (IF) (a surrogate for bacterial burden) **(C)**, number of bacterial foci **(D)** and spatial
distribution of bacteria **(E)**, in *stat2* CRISPants compared to control RNP injected siblings. Each data
point represents an individual zebrafish larva, lines and error bars indicate the median and
interquartile range. p values were derived from two-tailed Mann-Whitney tests. Data are
representative of four experiments.

Fig. 4. Reduced steady state neutrophil numbers in *stat2* CRISPants. (A) Representative images of three day post-fertilisation (dpf) control (upper panel) and *stat2* CRISPant (lower panel) *Tg(mpeg1:mCherry)* zebrafish larvae. Scale bar = 250 µm. **(B)** Integrated fluorescence (IF) as a surrogate for steady state macrophage numbers in three dpf *stat2* CRISPants compared to siblings injected with scrambled RNPs*. **(C)** Representative images of two dpf control (upper panel) and *stat2* CRISPant (lower panel) *Tg(mpx:eGFP)* zebrafish larvae. Scale bar = 250 µm. **(D)** Quantitation of baseline neutrophil numbers (represented by IF) in two dpf *stat2* CRISPants and negative control RNP injected siblings. Each data point represents an individual zebrafish larva, lines and error bars indicate the median and interquartile range. p values were derived from two-tailed Mann-Whitney tests. Data are from three independent experiments.

Fig. 5. Neutrophil recruitment to the site of sterile injury is not *stat2* dependent.
(A) Representative images of eGFP-expressing neutrophils recruited to the site of injury 1, 6 and 24
hours following tailfin transection of three day post-fertilisation *stat2* CRISPant *Tg(mpx:eGFP)*
zebrafish larvae and scrambled RNP injected controls. Scale bar represents 100 μm. **(B)** Distance
of neutrophils from the injury site at 1, 6 and 24 hours post-wound (hpw), derived by identifying the
Sholl circle in which the maximum integrated fluorescence (IF), a surrogate for highest cell numbers,
was detected in *stat2* CRISPants and scrambled RNP injected siblings. **(C-D)** IF, a surrogate for
total neutrophil numbers **(C)**, and IF at the wound site, representing neutrophil numbers localized to
the tailfin transection **(D)** are shown at 1, 6 and 24 hours following injury. On scatter plots data points
represent individual zebrafish larvae and lines and error bars the median and interquartile range. On
box and whisker plots horizontal lines represent median values, box limits indicate the interquartile
range and whiskers extend between the 5th and 95th percentiles. p values were derived from two-
tailed Mann-Whitney tests. * = p<0.05. Data are from three independent experiments. px = Pixels.

Fig. 6. Reduced macrophage recruitment to the site of sterile injury in *stat2* CRISPants.
(A) Representative images of mCherry-expressing macrophages recruited to the site of tailfin
transection by 6 and 24 hours, in three day post-fertilisation *stat2* CRISPant *Tg(mpeg1:mCherry)*
zebrafish embryos and controls. Scale bar represents 100 μm. **(B)** Comparison of the distance of
macrophages from the site of injury at the indicated time points for *stat2* CRISPants and control RNP
injected siblings. **(C)** Integrated fluorescence (IF) a surrogate for macrophage numbers at the site of
tailfin transection is shown at 1, 6 and 24 hours post-wound (hpw). On scatter plots data points
represent individual zebrafish larvae and lines and error bars the median and interquartile range. On
box and whisker plots horizontal lines represent median values, box limits indicate the interquartile
range and whiskers extend between the 5th and 95th percentiles. p values were derived from two-
tailed Mann-Whitney tests. * = p<0.05. Data are from three independent experiments. px = Pixels.

Fig. 7. Reduced macrophage and neutrophil recruitment to *M. marinum* in *stat2* CRISPants.
(A) Representative images of mCherry-expressing macrophages recruited to the hindbrain (dashed white outline) 18 hours following injection of PBS or 200 colony forming units (cfu) *M. marinum* in two day post-fertilisation (dpf) *stat2* CRISPant *Tg(mpeg1:mCherry)* zebrafish larvae and scrambled ribonucleoprotein (RNP) injected controls. **(B)** Number of macrophages recruited to the hindbrain in response to PBS or *M. marinum* in *stat2* CRISPants and negative control RNP injected siblings. **(C)** Representative images of eGFP-expressing neutrophils recruited to the hindbrain 6 hours after PBS or *M. marinum* injection (200 cfu) in two dpf *stat2* CRISPant and control *Tg(mpx:eGFP)* zebrafish larvae. **(D)** Quantitation of neutrophils recruited to the site of *M. marinum* infection in *stat2* CRISPants and control siblings. Scale bars represent 100 μm. Data points represent individual zebrafish larvae and lines and error bars the median and interquartile range. p values were derived from two-tailed Mann-Whitney tests. * = p<0.05. Data are from three independent experiments.

TABLES

Table 1. Clinical and demographic data summary. Demographic characteristics and magnitude
of clinical induration at the site of TST or saline injection are summarised for all study subjects.
Duration of anti-tuberculous drug treatment at the time of sampling and radiographic disease severity
data are provided for individuals with pulmonary TB. Saline samples were obtained from 17
individuals with pulmonary TB and 32 healthy participants who were people with cured or latent TB,
BCG vaccine recipients and healthy volunteers, described previously *(8)*. CXR = chest x-ray.
*Applies only to participants with active TB receiving saline injections.

		TST	Saline
Number		51	49
Age	(median and range)	30 (19-77)	28 (18-75)
Sex	Male	31 (61%)	19 (39%)
	Female	20 (39%)	30 (61%)
Ethnicity	White	21 (41%)	20 (41%)
	Asian	15 (29%)	8 (16%)
	Black	12 (24%)	7 (14%)
	Mixed	2 (4%)	1 (2%)
	South American	1 (2%)	11 (22%)
	Not recorded	NA	2 (4%)
Injection site induration (mm)	(median and range)	20 (0-70)	0
Days TB treatment before TST +/ saline	(median and range)	19 (0-30)	15 (0-28)*
CXR severity score	(median and range)	30 (0-140)	15 (0-110)*